Message

From:

CUBBAGE, JERRY W [AG/1000] [/O=MONSANTO/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=Z9JWCUBB74A]

Sent:

5/24/2017 4:28:21 PM

To:

HEMMINGHAUS, JOHN W [AG/1000] [john.w.hemminghaus@monsanto.com]

CC:

MURPHY, JENNY [AG/1000] [jenny.murphy@monsanto.com]; BHAKTA, TINA [AG/1000]

[tina.bhakta@monsanto.com]

Subject:

RE: REG-2017-0364

Jenny and John,

I will add both Sonic and Surveil to the website this week, unless either of you have concerns.

Thanks Jerry

From: HEMMINGHAUS, JOHN W [AG/1000] Sent: Wednesday, May 24, 2017 2:36 PM

To: CUBBAGE, JERRY W [AG/1000] < jerry.w.cubbage@monsanto.com> **Cc:** MURPHY, JENNY [AG/1000] < jenny.murphy@monsanto.com>

Subject: FW: REG-2017-0364

Jerry,

Here is the surveil data. Xtendimax and Xtend plus Surveil are ok. The tank mix of Powermax + Xtendimax + Surveil is numerically higher but within the error of the study. My recommendation is to approve per our third party approval guidelines and process.

John

From: GAVLICK, WALTER K [AG/1000]
Sent: Wednesday, May 24, 2017 9:04 AM

To: HEMMINGHAUS, JOHN W [AG/1000] < john.w.hemminghaus@monsanto.com>

Cc: FALKLER, SUSAN R [AG/1000] <susan.r.falkler@monsanto.com>

Subject: FW: REG-2017-0364

Sue is the study director since I was out at Battelle, but below are the LC-MS results. Viktar will need to finalize the lower level samples on the LC-MS/MS so these are preliminary results. Surveil does appear to increase volatility relative to non-Surveil treatments.

From: WEBB, JULIE K [AG-Contractor/1000]
Sent: Monday, May 22, 2017 1:37 PM

To: FALKLER, SUSAN R [AG/1000] <susan.r.falkler@monsanto.com>; GAVLICK, WALTER K [AG/1000]

<walter.k.gavlick@monsanto.com>

Subject: REG-2017-0364

Preliminary LC-MS results. Lower level samples are being reanalyzed on LC-MS/MS.

BADER FARMS ET AL V. MONSANTO ET AL.

EXHIBIT

PLTF-188

Confidential

MON0242804

